Tag Archives: Placebos

Kennedy Issues Demands for Vaccine Approvals That Could Affect Fall Covid Boosters

Kennedy Issues Demands for Vaccine Approvals That Could Affect Fall Covid Boosters

Health Secretary Robert F. Kennedy Jr. announced a plan that would require placebo-controlled studies for all new vaccines, surprising some experts who noted that such testing already routinely took place. In a statement, Andrew Nixon, a spokesman for the Department of Health and Human Services, said that “all new vaccines will undergo safety testing in placebo-controlled trials” before approval, and …

Read More »

FDA Approves Journavx Drug to Treat Pain Without Addiction Risk

FDA Approves Journavx Drug to Treat Pain Without Addiction Risk

The Food and Drug Administration approved a new medication Thursday to treat pain from an injury or surgery. It is expensive, with a list price of $15.50 per pill. But unlike opioid pain medicines, it cannot become addictive. That is because the drug, suzetrigine, made by Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside the …

Read More »

R.F.K. Jr., in His Own Words: Flu, Diabetes, Autism and More

R.F.K. Jr., in His Own Words: Flu, Diabetes, Autism and More

At Robert F. Kennedy Jr.’s confirmation hearings, beginning on Wednesday, senators are expected to question him closely about his controversial views on vaccines. For years Mr. Kennedy has questioned the safety of vaccines, including those for polio and measles, two diseases that continue to harm children. More recently, he has said that he’s not planning to take vaccines away from …

Read More »

Paxlovid Improved Long Covid Symptoms in Some Patients, Researchers Report

Paxlovid Improved Long Covid Symptoms in Some Patients, Researchers Report

Can Paxlovid treat long Covid? A new report suggests it might help some patients, but which patients might benefit remains unclear. The report, published Monday in the journal Communications Medicine, describes the cases of 13 long Covid patients who took extended courses of the antiviral drug. Results were decidedly mixed: Nine patients reported some improvement, but only five said it …

Read More »